SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Nuvo Research Inc
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark Bartlett who wrote (6721)2/10/2001 11:05:51 AM
From: DaveAu  Read Replies (1) of 14101
 
Mark,

<<Bottom line - if 5% skin irritation was the only problem in the study population, we are
in pretty good shape. >>

I don't recall hearing this 5% figure. At the AGM in the fall of 1999 we were told that the sensitization rate for Pennsaid was 0.8% versus between 2% and 6% for the topicals that have been approved for sale in Europe. I understood those figures to come from the controlled studies. This is a big advantage for Pennsaid that we haven't talked a lot about.

Dave
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News